# A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

> **NCT01371708** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 283 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** DVS SR

## Key facts

- **NCT ID:** NCT01371708
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-02
- **Primary completion:** 2016-04-22
- **Final completion:** 2016-04-22
- **Target enrollment:** 283 (ACTUAL)
- **Last updated:** 2017-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01371708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01371708, "A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01371708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*